BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 25791390)

  • 1. Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation.
    Nguyen DT; Shayani S; Palmer J; Dagis A; Forman SJ; Epstein J; Spielberger R
    Support Care Cancer; 2015 Nov; 23(11):3141-7. PubMed ID: 25791390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting.
    Stiff PJ; Emmanouilides C; Bensinger WI; Gentile T; Blazar B; Shea TC; Lu J; Isitt J; Cesano A; Spielberger R
    J Clin Oncol; 2006 Nov; 24(33):5186-93. PubMed ID: 16391299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.
    Goldberg JD; Zheng J; Castro-Malaspina H; Jakubowski AA; Heller G; van den Brink MR; Perales MA
    Bone Marrow Transplant; 2013 Jan; 48(1):99-104. PubMed ID: 22750997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
    Rzepecki P; Sarosiek T; Barzal J; Oborska S; Nurzynski P; Wasko A; Szczylik C
    J BUON; 2007; 12(4):477-82. PubMed ID: 18067205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
    Nasilowska-Adamska B; Rzepecki P; Manko J; Czyz A; Markiewicz M; Federowicz I; Tomaszewska A; Piatkowska-Jakubas B; Wrzesien-Kus A; Bieniaszewska M; Duda D; Szydlo R; Halaburda K; Szczepinski A; Lange A; Hellman A; Robak T; Skotnicki A; Jedrzejczak WW; Walewski J; Holowiecki J; Komarnicki M; Dmoszynska A; Warzocha K; Marianska B
    Bone Marrow Transplant; 2007 Nov; 40(10):983-8. PubMed ID: 17846600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial.
    Lucchese A; Matarese G; Manuelli M; Ciuffreda C; Bassani L; Isola G; Cordasco G; Gherlone E
    Minerva Stomatol; 2016 Feb; 65(1):43-50. PubMed ID: 26862696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palifermin in children undergoing autologous stem cell transplantation: a matched-pair analysis.
    Czyzewski K; Debski R; Krenska A; Wysocki M; Styczynski J
    Anticancer Res; 2014 Dec; 34(12):7379-82. PubMed ID: 25503176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, Pharmacokinetics, and Efficacy of Palifermin in Children and Adolescents with Acute Leukemias Undergoing Myeloablative Therapy and Allogeneic Hematopoietic Stem Cell Transplantation: A Pediatric Blood and Marrow Transplant Consortium Trial.
    Morris J; Rudebeck M; Neudorf S; Moore T; Duerst R; Shah AJ; Graham M; Aquino V; Morris C; Olsson B
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1247-1256. PubMed ID: 26968792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A supersaturated calcium phosphate solution seems to effectively prevent and treat oral mucositis in haematopoietic stem cell transplanted cancer patients - single centre experience.
    Wasko-Grabowska A; Rzepecki P; Oborska S; Barzal J; Mlot B; Gawronski K; Wasko M; Szczylik C
    J BUON; 2012; 17(2):363-8. PubMed ID: 22740219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and effects of palifermin for the treatment of oral mucositis in patients affected by acute lymphoblastic leukemia.
    Lucchese A; Matarese G; Ghislanzoni LH; Gastaldi G; Manuelli M; Gherlone E
    Leuk Lymphoma; 2016; 57(4):820-7. PubMed ID: 26428409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palifermin for oral mucositis after intensive therapy for hematologic cancers.
    Spielberger R; Stiff P; Bensinger W; Gentile T; Weisdorf D; Kewalramani T; Shea T; Yanovich S; Hansen K; Noga S; McCarty J; LeMaistre CF; Sung EC; Blazar BR; Elhardt D; Chen MG; Emmanouilides C
    N Engl J Med; 2004 Dec; 351(25):2590-8. PubMed ID: 15602019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.
    Langner S; Staber P; Schub N; Gramatzki M; Grothe W; Behre G; Rabitsch W; Urban C; Linkesch W; Neumeister P
    Bone Marrow Transplant; 2008 Aug; 42(4):275-9. PubMed ID: 18500368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT.
    Nasilowska-Adamska B; Szydlo R; Rzepecki P; Czyz A; Tomaszewska A; Markiewicz M; Torosian T; Bieniaszewska M; Hellman A; Jedrzejczak WW; Holowiecki J; Komarnicki M; Warzocha K; Marianska B
    Ann Transplant; 2011; 16(4):47-54. PubMed ID: 22210421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases.
    Vitale KM; Violago L; Cofnas P; Bishop J; Jin Z; Bhatia M; Kung AL; George D; Garvin J; Satwani P
    Pediatr Transplant; 2014 Mar; 18(2):211-6. PubMed ID: 24823628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant.
    Beaven AW; Shea TC
    Drugs Today (Barc); 2007 Jul; 43(7):461-73. PubMed ID: 17728847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
    Nooka AK; Johnson HR; Kaufman JL; Flowers CR; Langston A; Steuer C; Graiser M; Ali Z; Shah NN; Rangaraju S; Nickleach D; Gao J; Lonial S; Waller EK
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):852-857. PubMed ID: 24607557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
    Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation.
    Horsley P; Bauer JD; Mazkowiack R; Gardner R; Bashford J
    Support Care Cancer; 2007 Jan; 15(1):105-9. PubMed ID: 16896881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study.
    Le QT; Kim HE; Schneider CJ; Muraközy G; Skladowski K; Reinisch S; Chen Y; Hickey M; Mo M; Chen MG; Berger D; Lizambri R; Henke M
    J Clin Oncol; 2011 Jul; 29(20):2808-14. PubMed ID: 21670453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation.
    Anand A; Anandi P; Jain NA; Lu K; Dunavin N; Hourigan CS; Le RQ; Chokshi PD; Ito S; Stroncek DF; Sabatino M; Barrett AJ; Battiwalla M
    Support Care Cancer; 2016 Feb; 24(2):815-822. PubMed ID: 26190358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.